Segment, Geographical and Other Revenue Information (Tables)

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Schedule of segment reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

	Three months ended June 30, 2018								Three months ended June 30, 2017
	Performance Enzymes		Novel Biotherapeutics			Total			Performance Enzymes		Novel Biotherapeutics			Total
Revenues:
Product revenue	$	3,723	$	—		$	3,723		$	6,600	$	—		$	6,600
Research and development revenue	7,442		2,373			9,815			3,747		—			3,747
Total revenues	11,165		2,373			13,538			10,347		—			10,347
Costs and operating expenses:
Cost of product revenue	2,611		—			2,611			3,790		—			3,790
Research and development(1)	4,724		2,442			7,166			4,023		2,149			6,172
Selling, general and administrative	1,729		304			2,033			1,777		—			1,777
Total segment costs and operating expenses	9,064		2,746			11,810			9,590		2,149			11,739
Income (loss) from operations	$	2,101	$	(373	)	$	1,728		$	757	$	(2,149	)	$	(1,392	)
Corporate costs (2)						(5,209		)						(4,702		)
Depreciation and amortization						(265		)						(228		)
Loss before income taxes						$	(3,746	)						$	(6,322	)

⁽¹⁾ Research and development expenses exclude depreciation and amortization.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

	Six months ended June 30, 2018							Six months ended June 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total			Performance Enzymes			Novel Biotherapeutics			Total
Revenues:
Product revenue	$	9,886	$	—	$	9,886		$	12,186		$	—		$	12,186
Research and development revenue	12,008		5,686		17,694			6,131			—			6,131
Total revenues	21,894		5,686		27,580			18,317			—			18,317
Costs and operating expenses:
Cost of product revenue	6,436		—		6,436			6,792			—			6,792
Research and development(1)	9,790		4,374		14,164			8,172			3,660			11,832
Selling, general and administrative	3,825		450		4,275			3,589			—			3,589
Total segment costs and operating expenses	20,051		4,824		24,875			18,553			3,660			22,213
Income (loss) from operations	$	1,843	$	862	$	2,705		$	(236	)	$	(3,660	)	$	(3,896	)
Corporate costs (2)					(10,644		)							(9,308		)
Depreciation and amortization					(503		)							(554		)
Loss before income taxes					$	(8,442	)							$	(13,758	)

⁽¹⁾ Research and development expenses exclude depreciation and amortization.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):

	Three months ended June 30, 2018						Three months ended June 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	768	$	83	$	851	$	434	$	47	$	481

	Six months ended June 30, 2018						Six months ended June 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	1,326	$	146	$	1,472	$	789	$	100	$	889

Schedule of customers that contributed 10% or more of total accounts receivable

Customers that each contributed 10% or more of our total revenues were as follows:

	Percentage of Total Revenues for the
	Three Months Ended June 30,		Six Months Ended June 30,
	2018	2017	2018	2017
Customer A	27%	45%	38%	42%
Customer B	34%	21%	22%	12%
Customer C	18%	*	21%	*

Customers that each contributed 10% or more of our total accounts receivable had the following balances as of the periods presented:

	Percentage of Accounts Receivables at
	June 30, 2018	December 31, 2017
Customer A	46%	31%
Customer B	27%	16%
Customer D	11%	15%
Customer E	*	14%

* Less than 10% of the period presented

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Revenues
Americas	$	6,058	$	4,401	$	9,655	$	6,189
EMEA	3,808		1,959		8,800		5,166
APAC	3,672		3,987		9,125		6,962
Total revenues	$	13,538	$	10,347	$	27,580	$	18,317

Schedule of long-lived assets by geographical area

Identifiable long-lived assets as follows (in percentage):

Long-lived assets:	June 30, 2018		December 31, 2017
United States	100	%	100	%